Peter Chin Group Medical Director, Neuroscience, U.S. Medical Affairs, Genentech*
*While Peter was an employee at the time this article was published, he has since left Genentech.
Over the last 25 years, the scientific community has made significant advancements in understanding and treating multiple sclerosis (MS), which have helped transform what it means to live with the disease. Today, people diagnosed with MS have a far better chance of delaying disability, due to clinical advances in diagnosing MS faster and the availability of more medicines. But how do we move from delaying MS progression to stopping it or, perhaps someday in the future, even reversing it? This question is at the core of Genentech’s ongoing MS research.
Click HERE to Subscribe for the MS Beacon Newsletter
MS is a progressive disease from the start, regardless of how it manifests, and the biology of the disease is very complex. We believe that a better understanding of MS progression and being able to identify its underlying signs – paired with early treatment – could help tackle progression and preserve people’s day-to-day function over the long-term. Looking at MS from the first symptoms and signs of the disease is especially important in progressive forms of the disease, as disability tends to accumulate relentlessly.
Genentech has been conducting therapeutic clinical trials that aim to address unmet medical needs in Progressive MS for almost 15 years. With each clinical trial across the field, whether successful or not, we as a community learn a lot about the disease itself, which in turn enables us to design more sophisticated studies in the next round.
To watch additional videos and to read more, please click here